Cargando…

Role of tipranavir in treatment of patients with multidrug-resistant HIV

The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courter, Joshua D, Teevan, Colleen J, Li, Michael H, Girotto, Jennifer E, Salazar, Juan C
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952481/ https://www.ncbi.nlm.nih.gov/pubmed/20957134 http://dx.doi.org/10.2147/TCRM.S4207

Ejemplares similares

Review of tipranavir in the treatment of drug-resistant HIV
por: Streeck, Hendrik, et al.
Publicado: (2007)

Tipranavir in the Protease Inhibitors Arena
por: Vergani, Barbara, et al.
Publicado: (2012)

1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis
por: Stimes, Grant, et al.
Publicado: (2019)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
por: Hsieh, Szu-Min, et al.
Publicado: (2009)

Hepatic profile analyses of tipranavir in Phase II and III clinical trials
por: Mikl, Jaromir, et al.
Publicado: (2009)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands
por: Hubben, Gijs AA, et al.
Publicado: (2007)

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
por: Stefanik, Michal, et al.
Publicado: (2020)

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

Chemoinformatic Design and Profiling of Derivatives of Dasabuvir, Efavirenz, and Tipranavir as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase and Methyltransferase
por: Ezeh, Madeleine I., et al.
Publicado: (2022)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Index of Learning Styles in a U.S. School of Pharmacy
por: Teevan, Colleen J., et al.
Publicado: (2011)

Remarks on the Pathology and Treatment of Stricture of the Urethra
por: Teevan, W. F.
Publicado: (1871)

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
por: Cooper, David A., et al.
Publicado: (2016)

On the Diagnosis and Treatment of Stricture of the Urethra in Its Early Stage
por: Teevan, W. F.
Publicado: (1867)

An Inquiry into the Causation, Diagnosis, and Treatment of Fracture of the Internal Table of the Skull
por: Teevan, William Frederic
Publicado: (1865)

On Tumours in Voluntary Muscles; with an Analysis of Sixty-Two Cases, and Remarks on the Treatment
por: Teevan, W. F.
Publicado: (1863)

The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
por: Indu, Purushothaman, et al.
Publicado: (2020)

Viral escape in the CNS with multidrug-resistant HIV-1
por: Béguelin, Charles, et al.
Publicado: (2014)

The Role of Chloride Channels in the Multidrug Resistance
por: Wilczyński, Bartosz, et al.
Publicado: (2021)

Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV
por: Henderson, Heather I, et al.
Publicado: (2022)

Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru
por: Campos, Pablo E., et al.
Publicado: (2003)

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
por: Tierney, Dylan B., et al.
Publicado: (2016)

Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India
por: Isaakidis, Petros, et al.
Publicado: (2013)

Multidrug resistance associated proteins in multidrug resistance
por: Sodani, Kamlesh, et al.
Publicado: (2012)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Candida albicans exhibit two classes of cell surface binding sites for serum albumin defined by their affinity, abundance and prospective role in interkingdom signalling
por: Teevan-Hanman, Claire, et al.
Publicado: (2021)

Cases Illustrating the Efficacy of Arsenic in Intermittent Fever
por: Teevan, William
Publicado: (1827)

906. Surgical Site Infections in Children with Beta-Lactam Allergy: A Matched Cohort Study
por: Huang, Felicia Scaggs, et al.
Publicado: (2020)

Diagnosis and treatment of multidrug-resistant tuberculosis
por: Jang, Jong Geol, et al.
Publicado: (2020)

Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria
por: Aliyu, Gambo, et al.
Publicado: (2013)

Intrathecal/Intraventricular Linezolid in Multidrug-Resistant Enterococcus faecalis Ventriculitis
por: Lich, Brian F., et al.
Publicado: (2016)

The Roles of microRNAs in Cancer Multidrug Resistance
por: Pavlíková, Lucia, et al.
Publicado: (2022)

The Role of microRNAs in Multidrug Resistance of Glioblastoma
por: Mahinfar, Parvaneh, et al.
Publicado: (2022)

Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis
por: Reuter, Anja, et al.
Publicado: (2023)

Reversal of multidrug resistance by surfactants.
por: Woodcock, D. M., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_vji86e1jsemf2sovkd89u20un5